NO961900D0 - Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid - Google Patents

Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid

Info

Publication number
NO961900D0
NO961900D0 NO961900A NO961900A NO961900D0 NO 961900 D0 NO961900 D0 NO 961900D0 NO 961900 A NO961900 A NO 961900A NO 961900 A NO961900 A NO 961900A NO 961900 D0 NO961900 D0 NO 961900D0
Authority
NO
Norway
Prior art keywords
ifosfamide
prophylaxis
treatment
methylene blue
encephalopathy caused
Prior art date
Application number
NO961900A
Other languages
English (en)
Other versions
NO961900L (no
Inventor
Adrian Kuepfer
Thomas Cerny
Original Assignee
Univ Newcastle Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Newcastle Ventures Ltd filed Critical Univ Newcastle Ventures Ltd
Publication of NO961900D0 publication Critical patent/NO961900D0/no
Publication of NO961900L publication Critical patent/NO961900L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO961900A 1993-11-12 1996-05-10 Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid NO961900L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323399A GB9323399D0 (en) 1993-11-12 1993-11-12 Pharmaceutical formulations
PCT/GB1994/002494 WO1995013079A1 (en) 1993-11-12 1994-11-14 Methylene blue for the treatment or prophylaxis of ancephalopathy caused by ifosfamide

Publications (2)

Publication Number Publication Date
NO961900D0 true NO961900D0 (no) 1996-05-10
NO961900L NO961900L (no) 1996-05-10

Family

ID=10745089

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961900A NO961900L (no) 1993-11-12 1996-05-10 Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid

Country Status (9)

Country Link
US (1) US5854240A (no)
EP (1) EP0728005A1 (no)
JP (1) JPH09505042A (no)
CN (1) CN1134670A (no)
AU (1) AU8149594A (no)
CA (1) CA2176386A1 (no)
GB (1) GB9323399D0 (no)
NO (1) NO961900L (no)
WO (1) WO1995013079A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
US7176192B2 (en) * 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
CA2379211A1 (fr) * 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
US20060188866A1 (en) * 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
GR1006794B (el) * 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση
JP2010184936A (ja) * 2010-06-01 2010-08-26 Bionumerik Pharmaceuticals Inc 放射線被爆患者の処置方法
CN114728189A (zh) * 2019-11-11 2022-07-08 日本先端株式会社 抗癌剂暴露防止方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1645921C3 (de) * 1966-07-11 1978-10-12 Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld 2-Oxo-13,2-osazaphosphorinane, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
US4548927A (en) * 1983-05-25 1985-10-22 Eaton John W Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics
WO1986004679A1 (en) * 1985-02-12 1986-08-14 Commonwealth Scientific And Industrial Research Or Voltammetric cell

Also Published As

Publication number Publication date
CA2176386A1 (en) 1995-05-18
EP0728005A1 (en) 1996-08-28
GB9323399D0 (en) 1994-01-05
US5854240A (en) 1998-12-29
CN1134670A (zh) 1996-10-30
JPH09505042A (ja) 1997-05-20
WO1995013079A1 (en) 1995-05-18
AU8149594A (en) 1995-05-29
NO961900L (no) 1996-05-10

Similar Documents

Publication Publication Date Title
FI962249A7 (fi) Substituoituja pyratsolyylibentseenisulfonamideja tulehduksen hoitoa varten
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
NO914092D0 (no) Fremgangsmaate for fremstilling av mercaptoacetylamidderivater
NO921777L (no) Fremgangsmaate for fremstilling av isoparaffiner
NO963785D0 (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
DE69530860D1 (de) Behandlung der entzündung des sehnervs
NO913689L (no) Fremgangsmaate ved fremstilling av silisiumbarrer med hoey renhet.
NO953371D0 (no) Anvendelse av anti-konvulsiva ved behandling av neuro-AIDS
FI945599L (fi) Fosfonokarboksylaattiyhdisteitä epänormaalin kalsium- ja fosfaattiaineenvaihdunnan hoitamiseksi
ATE267180T1 (de) Phosphorderivate zur behandlung von aids
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
NO933904L (no) Fremgangsmåte for fremstilling av aromatiske brommetylforbindelser
NO912548L (no) Fremgangsmaate for behandling av avfallsprodukter.
NO961900D0 (no) Metylenblått for behandling eller profylakse av encefalopati forårsaket av ifosfamid
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
CA2141563A1 (en) Novel 2-Substituted Indane-2-Mercaptoacetylamide Tricyclic Derivatives Useful as Inhibitors of Enkephalinase
FI961380A7 (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitam iseksi
NO932850L (no) Fremgangsmaate for fremstilling av staal
NO941659L (no) Fremgangsmåte for fremstilling av aluminoksaner
NO934832D0 (no) Farmasoeytisk sammensetning for forhindring eller behandling av ar terioscherose
NO920467L (no) Framgangsmaate for framstilling av oppmalte naeringsmidler
NO306065B1 (no) Fremgangsmåte for fremstilling av organoklorsilaner
FI944687L (fi) Koostumus likinäköisyyden ennaltaehkäisemiseksi ja hoitamiseksi